Recent Finacing
Recent Raise
Stamford Pharmaceuticals is a clinical-stage biotechnology company developing SP-002, an adenoviral-based immunotherapy, and conducting a Phase 2 trial combining SP-002 with a Hedgehog pathway inhibitor for laBCC.
Focus Areas
Recent Investors
Funding round
Investors
See the team members at Stamford Pharmaceuticals.
